Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Neovacs SA ( (FR:ALNEV) ) is now available.
Néovacs has announced an independent valuation of its mRNA research program in severe asthma, valued between €56 and €98 million, with potential to reach up to €402 million following successful clinical trials. The company is seeking partners to support the clinical development phase, emphasizing that this is not due to a lack of resources but to validate its approach and share project risks.
More about Neovacs SA
Néovacs is a French biotechnology company engaged in R&D and investment activities, focusing on vaccine candidates for lupus and allergies using its kinoid® technology platform. The company specializes in active immunotherapy to regulate harmful protein overproduction.
YTD Price Performance: -95.73%
Average Trading Volume: 11,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €18.87K
For a thorough assessment of ALNEV stock, go to TipRanks’ Stock Analysis page.